Inferra AI / Company / ASTH

Astrana Health, Inc.

ASTH · Health Care

Last earnings Aug 6, 2026

Key results

Total revenuequarter

$654.8 million

Total revenue of $654.8 million, up 35% from $486.3 million &bull

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Growthquarter

up 35%

Total revenue of $654.8 million, up 35% from $486.3 million &bull

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Care Partners revenuequarter

$631.4 million

Care Partners revenue of $631.4 million, up 36% from $463.3 million &bull

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Total revenue of $1,275.2 million, up 43% from $890.6 million &bull

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Care Partners revenue of $1,232.4 million, up 46% from $845.6 million &bull

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

AI analysis

Q2 2025 · reported Aug 7, 2025

Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held

Total revenue · Q2 2025

$654.8M

EX-99 · Aug 7, 2025

Care Partners revenue · Q2 2025

$631.4M

EX-99 · Aug 7, 2025

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

Q2 2025 delivered$654.8M

Guided range (company-stated)$0.7B · midpoint $0.7B

0$B

EX-99 · Aug 7, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

Metric	Q2 2025	Prior qtr	Year ago
Total revenue	$654.8 million	—	—
Growth	up 35%	—	—
Care Partners revenue	$631.4 million	—	—

EX-99 · Aug 7, 2025

Guidance · company-stated

Direction: Reiterated

Revenue$654.8 million

“ET · Reports total revenue of $654.8 million and adjusted EBITDA of $48.1 million, both at the higher end of guidance · Continues to manage medical cost trends effectively, with trend within expectations across all lines of business · Reiterates full-year 2025 guidance which is inclusive of the now-closed Prospect Health acquisition ALHAMBRA, Calif.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

The acquisition was financed using $707.3 million of proceeds from a five-year delayed draw term loan credit facility.

(3) Other, net for the six months ended June 30, 2025, relates to debt issuance costs expensed in connection with our Second Amended and Restated Credit Facility, transaction costs for our acquisition of Prospect Health, data transition costs for our recent acquisitions, certain costs associated with the CHS transaction, non-cash changes related to change in the fair value of our call option and Collar Agreement, and severance fees incurred.

What changed vs last quarter

Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Reports Second Quarter 2025 Results Company to Host Conference Call on Thursday, August 7, 2025, at 2:30 p.m

Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Reiterated

Revenue: “ET · Reports total revenue of $654.8 million and adjusted EBITDA of $48.1 million, both at the higher end of guidance · Continues to manage medical cost trends effectively, with trend within expectations across all lines of business · Reiterates full-year 2025 guidance which is inclusive of the now-closed Prospect Health acquisition ALHAMBRA, Calif.”

Revenue — Reiterated (“Reiterates”)
“ET · Reports total revenue of $654.8 million and adjusted EBITDA of $48.1 million, both at the higher end of guidance · Continues to manage medical cost trends effectively, with trend within expectations across all lines of business · Reiterates full-year 2025 guidance which is inclusive of the now-closed Prospect Health acquisition ALHAMBRA, Calif.”

Revenue — Reiterated (“reiterating”)
“2025 Guidance: Astrana is providing the following guidance for total revenue and Adjusted EBITDA for the quarter ending September 30, 2025 and reiterating guidance for the year ending December 31, 2025 based on the Company’s existing business, current view of existing market conditions, and assumptions.”

Classified from the release's primary full-year outlook statement.

Capital allocation

The acquisition was financed using $707.3 million of proceeds from a five-year delayed draw term loan credit facility.

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

These reclassifications were made to (i) the condensed consolidated balance sheet as of December 31, 2025 to reclassify investments in privately held entities to other assets within non-current assets; and (ii) the condensed consolidated statement of cash flows for the six months ended June 30, 2025 to reclassify (a) change in fair value of contingent consideration liabilities from other within net cash provided by operating activities, (b) the issuance of loans receivable to other within net cash used in investing activities, and (c) payment of contingent liabilities and repurchase of treasury shares from other within net cash used in financing activities.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

To finance the acquisition, the Company borrowed $ 707.3 million from a five-year delayed draw term loan credit facility.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

See Note 8 Credit Facility and Bank Loans for further information on the Company s debt.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The pro forma financial information presented has been adjusted to exclude Prospect s historical interest expense as all outstanding debt obligations were settled at closing and not assumed by the Company.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Strategy & priorities

As we look ahead, we remain focused on disciplined execution and expanding access to high-quality, coordinated care for the patients and communities we serve.

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

McBride's appointment complements several other strategic additions to the leadership team, including Georgie Sam as Chief Data and Analytics Officer, Glenn Sobotka as Chief Accounting Officer, and the promotion of Rita Pew to Chief People Officer.

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Segments The Company s three reportable segments are Care Partners, Care Delivery, and Care Enablement, which are described as follows: Care Partners The Company s Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

9 Table of Contents Care Delivery The Company s Care Delivery segment is a group of patient-centric, data-driven organizations focused on delivering high-quality, accessible care to all patients.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Risks & headwinds

Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent quarterly reports on Form 10-Q.

SEC original ↗Astrana Health, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Forward-looking statements involve risks and uncertainties, many of which are difficult to predict, are outside of our control, and are based on the current beliefs, expectations, and certain assumptions of management.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Significant risks and uncertainties could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements.

SEC original ↗Astrana Health, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Documents

Earnings deck slides

0 decks with slide view

Astrana Health, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors